Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000687587 | SCV000815163 | uncertain significance | Bloom syndrome | 2022-06-13 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 386 of the BLM protein (p.Ile386Val). This variant is present in population databases (rs757636363, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with BLM-related conditions. ClinVar contains an entry for this variant (Variation ID: 567488). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV001010017 | SCV001170159 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-08-05 | criteria provided, single submitter | clinical testing | The p.I386V variant (also known as c.1156A>G), located in coding exon 5 of the BLM gene, results from an A to G substitution at nucleotide position 1156. The isoleucine at codon 386 is replaced by valine, an amino acid with highly similar properties. This variant was identified in a patient with breast cancer undergoing whole exome sequencing (Thompson ER et al. PLoS Genet, 2012 Sep;8:e1002894). This variant was also detected in a study of 1046 familial colorectal cancer cases and 1006 unrelated controls (Raskin L et al. Oncotarget, 2017 Nov;8:93450-93463). This amino acid position is well conserved in available vertebrate species; however, valine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000687587 | SCV001460772 | uncertain significance | Bloom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |